---
url: https://www.servicesaustralia.gov.au/primary-hyperoxaluria-type-1
title: Primary hyperoxaluria type 1 - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:36.045Z
source: servicesaustralia.gov.au
---
# Primary hyperoxaluria type 1

The PBS subsidises lumasiran for patients with primary hyperoxaluria type 1.

## on this page

-   [Patient eligibility](#a1)
-   [Treatment specifics](#a2)
-   [Authority applications](#a3)
-   [More information](#a4)

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with lumasiran under the _National Health Act 1953,_ section 85 for patients with primary hyperoxaluria type 1.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home;jsessionid=jrrab7f28xtjycras12yiccu) on the PBS website outlines the restrictions for prescribing lumasiran.

## Treatment specifics

To be eligible for PBS-subsidised treatment with lumasiran, patients must be treated by or in consultation with either a:

-   nephrologist with experience in the management of hyperoxaluria
-   paediatrician with experience in the management of hyperoxaluria.

## Authority applications

### Applying for initial treatment

Please note: You don’t need to complete this application in writing when you request [PBS authority online](/apply-for-pbs-authority?context=20#accordion1).

Applications for initial authority approval to prescribe PBS-subsidised lumasiran to treat primary hyperoxaluria type 1 can be made:

-   using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   in writing and using [HPOS Form upload](/upload-forms-hpos?context=20)
-   in writing and mailed to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [primary hyperoxaluria type 1 - lumasiran - initial authority application form](/pb389?context=20)
-   relevant attachments.

### Applying for initial grandfather treatment

Please note: You don’t need to complete this application in writing when you request [PBS authority online](/apply-for-pbs-authority?context=20#accordion1).

Applications for initial grandfather authority approval to prescribe PBS-subsidised lumasiran to treat primary hyperoxaluria type 1 can be made:

-   using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   in writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   in writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [primary hyperoxaluria type 1 - lumasiran - initial grandfather authority application form](/pb391?context=20)
-   relevant attachments.

### Applying for continuing treatment

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

Applications for continuing authority approval to prescribe PBS-subsidised lumasiran to treat primary hyperoxaluria type 1 can be made in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [primary hyperoxaluria type 1 - lumasiran - continuing authority application form](/pb390?context=20)
-   relevant attachments.

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
